MedTrace Logo

Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus

NCT05779644 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2023-05-16

No results posted yet for this study

Summary

The purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.

Conditions

  • Metformin
  • Obesity, Abdominal
  • Diabetes Mellitus, Type 2
  • Abdominal Fat
  • Non-Alcoholic Fatty Liver Disease
  • Metabolism Disorder, Glucose
  • Metabolism Disorder, Lipid

Interventions

DRUG

Liraglutide

Liraglutide is injected once a day.

DRUG

Semaglutide

Semaglutide is injected once a week.

DRUG

Metformin

Metformin is taken orally daily.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2025-02-23
Completion
2025-02-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05779644 on ClinicalTrials.gov